Ophthalmic interventions offer best value gains

Therapeutic interventions, in particular for neovascular age-related macular degeneration (AMD) offer a better degree of value than any other treatment right across the field of healthcare.

Related Content:

Articles

Application for Genentech’s faricimab accepted by U.S. FDA for treatment of wet AMD and DMO

Expanding the definition of AMD

Combined MIGS and cataract surgery option offers positive results